medmix AG

MEDXZ IX

MEDXZ IXmedmix AG

CBOE CXE EUR

16.10

CHF

-0.22

(-1.35%)

0.01EPS Dil.

1,610.00P/E

660.10MMarket Cap

2.30%Div. Yield

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

medmix AG

MEDXZ:IX

(CBOE CXE EUR)

Recent

price

16.10

P/E

ratio

- -

div

yld

- -

ROIC.AI

Legends:

Stock price

Beta (1.0 Market)

% total return 06/14

Stock

S&P500

2018	2019	2020	2021	2022	2023	TTM
11	10.2	8.51	11.11	11.65	11.91	11.95	Revenue per Share
1.27	0.61	0.23	1.07	0.28	0.01	0.01	Basic EPS, GAAP
1.56	1.28	0.18	1.35	0.22	0.08	0.24	Free Cash Flow per Basic Share
1.14	1.33	1.26	1	0.37	0.37	0.37	Dividend per Share
8.23	7.15	8.08	0.01	13.22	13	13	Book Value per Share
-1.01	-1.44	-2.14	3.41	3.17	1.92	1.92	Tangible Book Value per Share
41	41	41	41	41	41	41	Basic Weighted Avg Shares
454	421	351	457	477	487	487	Sales/Revenue/Turnover
14.76	12.79	5.81	13.75	10.38	2.92	2.92	Operating Margin (%)
43	43	43	52	51	58	58	Depreciation Expense
52	25	10	44	12	- -	- -	Net Income, GAAP
6.77	18.45	7.62	14.23	4.92	75.86	- -	Effective Tax Rate (%)
11.5	5.99	2.73	9.62	2.43	0.06	0.06	Profit Margin (%)
122	81	20	222	218	130	130	Working Capital
250	259	279	297	309	308	308	LT Debt
340	295	333	534	505	474	474	Total Equity
- -	7.39	3.02	7.03	5.1	0.38	- -	Return on Invested Capital (%)
- -	5.32	2.7	10.32	2.66	0.25	- -	Return on Capital (%)
- -	7.94	3.05	26.36	4.29	0.06	0.06	Return on Common Equity (%)

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	- -	2.53%	1.99%
Net Income, GAAP	- -	14.73%	-97.41%
Free Cash Flow	- -	77.41%	-64.44%
Total Cash Common Dividend	- -	- -	- -
Total Equity	- -	9.7%	-6.02%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Business: Medmix AG designs, develops, manufactures, and delivers high-precision devices and services for the mixing, application, and injection of liquids in a range of viscosities for the healthcare, consumer, and industrial end markets worldwide. The company operates through five segments: Dental, Drug Delivery, Surgery, Industry, and Beauty. The Dental segment offers mixing tips, dispensers, needles, accessories, and service solutions for various applications, such as prosthetics, restorations, anesthetics, and aesthetics. The Drug Delivery segment offers drug delivery devices that are used to inject fertility drugs and growth hormones; and to treat niche diabetes indications, osteoporosis, and rare diseases. The Surgery segment provides mixing and delivery devices which are used to inject bone tissue, and to apply hemostatic sealants for internal and external wound treatment during surgical procedures. The Industry segment produces and markets dispensers, cartridges, and mixers for two-component adhesives and sealants for use in the construction, transportation, electronics assembly, infrastructure, and DIY industries The Beauty segment offers micro-brushes used for the application of makeup treatments, such as lash & brow serum or spot correctors, as well as for the application of skincare treatments, such as anti-aging serums. It offers its products under the Mixpac, Transcodent, Cox, MK, Medmix, Haselmeier, and Geka brands. The company was founded in 1922 and is headquartered in Baar, Switzerland.

	Dec'22	Jun'23	Dec'23
ST Debt	164	10	42
LT Borrowings	247	247	247
LT Finance Leases	62	60	60
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	41	41	41
Market Capitalization	716	928	769

2018	2019	2020	2021	2022	2023	TTM
11	10.2	8.51	11.11	11.65	11.91	11.95	Revenue per Share
1.27	0.61	0.23	1.07	0.28	0.01	0.01	Basic EPS, GAAP
1.56	1.28	0.18	1.35	0.22	0.08	0.24	Free Cash Flow per Basic Share
1.14	1.33	1.26	1	0.37	0.37	0.37	Dividend per Share
8.23	7.15	8.08	0.01	13.22	13	13	Book Value per Share
-1.01	-1.44	-2.14	3.41	3.17	1.92	1.92	Tangible Book Value per Share
41	41	41	41	41	41	41	Basic Weighted Avg Shares
454	421	351	457	477	487	487	Sales/Revenue/Turnover
14.76	12.79	5.81	13.75	10.38	2.92	2.92	Operating Margin (%)
43	43	43	52	51	58	58	Depreciation Expense
52	25	10	44	12	- -	- -	Net Income, GAAP
6.77	18.45	7.62	14.23	4.92	75.86	- -	Effective Tax Rate (%)
11.5	5.99	2.73	9.62	2.43	0.06	0.06	Profit Margin (%)
122	81	20	222	218	130	130	Working Capital
250	259	279	297	309	308	308	LT Debt
340	295	333	534	505	474	474	Total Equity
- -	7.39	3.02	7.03	5.1	0.38	- -	Return on Invested Capital (%)
- -	5.32	2.7	10.32	2.66	0.25	- -	Return on Capital (%)
- -	7.94	3.05	26.36	4.29	0.06	0.06	Return on Common Equity (%)

	Dec'22	Jun'23	Dec'23
Total Current Assets	489	340	308
Accounts Receivable, Net	60	67	57
Cash, Cash Equivalents & STI	317	153	131
Inventories	92	97	88
Total Current Liabilities	271	148	178
Payables & Accruals	59	91	83
ST Debt	164	10	42
Deferred Revenue	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2021	0.55	0.52	- -	- -	1.07
2022	0.23	0.06	- -	- -	0.28
2023	0.18	-0.17	- -	- -	0.01